Prognostic Value of 18F-FDG PET in Primary Central Nervous System Lymphoma
Authors:
- Ga-Young SongGSGa-Young Song
- Ho Cheol JangHJHo Cheol Jang
- Mihee KimMKMihee Kim
- Seo-Yeon AhnSASeo-Yeon Ahn
- Sung-Hoon JungSJSung-Hoon Jung
- Jae-Sook AhnJAJae-Sook Ahn
- Je-Jung LeeJLJe-Jung Lee
- Hyeoung-Joon KimHKHyeoung-Joon Kim
- Jang Bae MoonJMJang Bae Moon
- Su Woong YooSYSu Woong Yoo
- Seong-Young KwonSKSeong-Young Kwon
- Jung-Joon MinJMJung-Joon Min
Open Access
- 17 February 2025
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 50 (4) , 281-288
Abstract
Purpose of the Report: The usefulness of brain 18F-FDG PET/CT in primary central nervous system lymphoma (PCNSL) remains underexplored. This study investigated whether early metabolic responses in interim brain FDG PET/CT serve as a prognostic indicator of PCNSL treatment outcomes. Patients and Methods: This prospective study included 53 patients with PCNSL who underwent a high-dose methotrexate–based treatment. Brain FDG PET was performed at diagnosis (baseline PET) and after induction chemotherapy (interim PET), assessing interim PET parameters such as the highest maximum standardized uptake value (hSUVmax), sum of SUVmax (sumSUVmax), highest tumor-to-normal ratio (hTNRmax), sum of TNRmax (sumTNRmax), highest metabolic tumor volume (MTV) (hMTV), and sum of MTV (sumMTV) across all PET-positive lesions. Results: High interim hTNRmax (hazards ratio: 9.76, 95% confidence interval: 1.90–50.11, P = 0.01) was an independently significant predictor of poor progression-free survival in multivariate analysis. Patients with low interim hTNRmax (≤1.0) had a significantly longer median progression-free survival than those with high interim hTNRmax (>1.0) (25.0 vs 3.6 months, P < 0.001). Incorporating interim MRI-based clinical response assessments and hTNRmax allowed the classification of partial response subgroups with markedly different prognoses (P < 0.001). High interim hTNRmax (hazards ratio: 2.76, 95% confidence interval: 1.39–5.48, P = 0.004) was an independently significant predictor of poor overall survival in multivariate analysis. Conclusions: The hTNRmax measurement from interim brain FDG PET scans emerges as an important prognostic marker in PCNSL. These findings underscore the potential of interim FDG PET evaluations to refine response assessments and inform tailored therapeutic strategies.Keywords
This publication has 40 references indexed in Scilit:
- Prognostic value of [18F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapiesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- Primary central nervous system lymphoma in patients with and without HIV infection: a multicenter study and comparison with U.S national dataCancer Causes & Control, 2019
- Interim 18F-FGD PET/CT may not predict the outcome in primary central nervous system lymphoma patients treated with sequential treatment with methotrexate and cytarabineAnnals of Hematology, 2017
- Hypoxic glucose metabolism in glioblastoma as a potential prognostic factorEuropean Journal of Nuclear Medicine and Molecular Imaging, 2016
- The diagnostic role of 18F-FDG PET for primary central nervous system lymphomaAnnals of Nuclear Medicine, 2014
- Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factorsJournal of Neuro-Oncology, 2006
- FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-upEuropean Journal of Nuclear Medicine and Molecular Imaging, 2005
- A metaanalysis of 18F‐2‐deoxy‐2‐fluoro‐D‐glucose positron emission tomography in the staging and restaging of patients with lymphomaCancer, 2005
- Can the standardized uptake value characterize primary brain tumors on FDG-PET?European Journal of Nuclear Medicine and Molecular Imaging, 1999
- Cerebral lymphoma presenting as a nonenhancing lesion on computed tomographic/ magnetic resonance scanAnnals of Neurology, 1993